Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reissue Patent
2008-02-06
2010-10-26
Azpuru, Carlos A (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S502000, C428S402210, C264S004300, C977S700000, C977S904000
Reissue Patent
active
RE041884
ABSTRACT:
Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations.
REFERENCES:
patent: 4006025 (1977-02-01), Swank et al.
patent: 4855221 (1989-08-01), Factor et al.
patent: 4973465 (1990-11-01), Baurain et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5091188 (1992-02-01), Haynes
patent: 5118528 (1992-06-01), Fessi et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5175287 (1992-12-01), Lee et al.
patent: 5188837 (1993-02-01), Domb
patent: 5318767 (1994-06-01), Liversidge et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5565188 (1996-10-01), Wong et al.
patent: 5834025 (1998-11-01), de Garavilla et al.
patent: 3722837 (1989-01-01), None
patent: 0233559 (1992-05-01), None
Wikipedia, “rate of infusion”, 2008.
de Garavilla, et al., “Controlling the Acute Hemodynamic Effects Associated With IV Administration of Particulate Drug Dispersions in Dogs,” Drug Development Research 37:86-96 (1996).
Information Disclosure Statement filed in U.S. Appl. No. 07/647,105 on Nov. 18, 1991.
Rule 132 Declaration of Eugene Cooper filed in U.S. Appl. No. 07/647,105 on Nov. 18, 1991.
Amendment filed in U.S. Appl. No. 07/647,105 on Nov. 18, 1991.
Information Disclosure Statement filed in U.S. Appl. No. 07/908,125 on Nov. 12, 1992.
Amendment filed in U.S. Appl. No. 07/908,125 on Sep. 13, 1993.
Rule 132 Declaration of Gary S. Liversidge filed in U.S. Appl. No. 07/908,125 on Sep. 13, 1993.
Information Disclosure Statement filed in U.S. Appl. No. 07/908,125 on Sep. 13, 1993.
Amendment filed in U.S. Appl. No. 07/908,125 on Jun. 27, 1994.
“Dynamic Light Scattering: An Introduction in 30 Minutes,” Malvern Instruments Limited, DLS technical note MRK656-01.
Haskell, “Nanotechnology for Drug Delivery,” Pfizer, Inc.
O'Donovan et al., “Sensitivity to Penicillin: Anaphylaxis and Desensitisation,” The Lancet, vol. CCLI, vol. 2, Sep. 28, 1946, pp. 444-446.
Lorenz et al., “Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent,” Agents Actions. Mar. 1977; 7(1):63-7.
Slack et al., “Acute Hemodynamic effects and blood pool kinetics of polystyrene microspheres following intravenous administration,” J Pharm Sci. Jun. 1981; 70(6):660-4.
Sullivan, “Antigen-specific desensitization of patients allergic to penicillin,” J Allergy Clin Immunol. Jun. 1982; 69(6):500-8.
Wendel et al., “Penicillin allergy and desensitization in serious infections during pregnancy,” N Engl J Med. May 9, 1985;312(19):1229-32.
“Remington's Pharmaceutical Sciences,” Mack Publishing Company, Easton, Pennsylvania, 1985, pp. 1585-1602.
Greenberger et al., “Emergency administration of radiocontrast media in high-risk patients,” J Allergy Clin Immunol. Apr. 1986; 77(4):630-4.
Borish et al., “Intravenous desensitization to beta-lactam antibiotics,” J Allergy Clin Immunol. Sep. 1987; 80(3 Pt 1): 314-9.
Faithfull et al., “Cardiorespiratory consequences of fluorocarbon reaction in dogs,” Biomater Artif Cells Artif Organs. 1988;16(1-3):463-72.
Weiss et al., “Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512),” Cancer Res. Oct. 15, 1988;48(20):5878-82.
Budavari et al., “The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals” Eleventh Edition, 1989, pp. 262, 610, 1188, 1298, 1299, 1435, THER-16, THER-17.
Gennaro et al., “Remington's Pharmaceutical Sciences,” Eighteenth Edition, Mack Publishing Company, Easton, Pennsylvania, 1990, pp. 768, 948, 968, 986, 988, 990-993, 998, 1001, 1138-1163, 1238-1240.
Rowinsky et al., “Taxol: a novel investigational antimicrotubule agent,” J Natl Cancer Inst. Aug. 1, 1990;82(15):1247-59.
Greenberger et al., “The prevention of immediate generalized reactions to radiocontrast media in high-risk patients,” J Allergy Clin Immunol. Apr. 1991; 87(4):867-72.
Levine et al., “Cardiopulmonary toxicity after liposomal amphotericin B infusion,” Ann Intern Med. Apr. 15, 1991;114(8):664-6.
Shchipunov et al., “Phospholipids at the oil/water interface: adsorption and interfacial phenomena in an electric field,” Adv Colloid Interface Sci. Mar. 1991; 35:31-138.
Valero et al., “Adverse reactions to vancomycin prophylaxis in cardiac surgery,” J Cardiothorac Vasc Anesth. Dec. 1991; 5(6):574-6.
Fisher-Hoch et al., “Unexpected adverse reactions during a clinical trial in rural west Africa,” Antiviral Res. Aug. 1992; 19(2):139-47.
Cowens et al., “Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes),” Cancer Res. Jun. 15, 1993;53(12):2796-802.
Misbah et al., “Adverse effects of intravenous immunoglobulin,” Drug Saf. Oct. 1993; 9(4):254-62.
Katz et al., “Amphotericin B And Hypertension,” The Pediatric Infectious Disease Journal, vol. 13, No. 9, Sep. 1994, pp. 839-840.
Kirkwood et al., “Current Cancer Therapeutics,” First Edition, Current Medicine, p. 78, 1994.
Wong et al., “Vancomycin hypersensitivity: synergism with narcotics and “desensitization” by a rapid continuous intravenous protocol,” J Allergy Clin Immunol. Aug. 1994; 94(2 Pt 1):189-94.
Gill et al., “Phase I/II Clinical and Pharmacokinetic Evaluation of Liposomal Daunorubicin,” Journal of Clinical Oncology, vol. 13, No. 4 (Apr. 1995): pp. 996-1003.
Kattan et al., “Phase I Clinical Trial and pharmacokinetic Evaluation of Doxorubicin Carried by Polyisohexylcyanoacrylate Nanoparticles,” Investigational New Drugs, 10:191-199, 1992.
Kleinerman et al., “Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma,” Am J Clin Oncol. Apr. 1995; 18(2):93-9.
Schwartz et al., “A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma,” Invest New Drugs. 1995;13(1):77-82.
Uziely et al., “Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies,” J Clin Oncol. Jul. 1995; 13(7):1777-85.
van Nieuwenhuyzen et al., “Effects of lecithins and proteins on the stability of emulsions,” Fett/Lipid 100 (1998), Nr. 7, S. 282-291.
Bertrand et al., “Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators,” Circulation. Jan. 18, 2000;101(2):131-6.
Sneader, “The discovery of aspirin: a reappraisal,” BMJ Dec. 23-30, 2000;321(7276):1591-4.
Wong et al., “Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema,” J Allergy Clin Immunol. May 2000; 105(5):997-1001.
“Advertising Information for AZoNano.com for 2007,” http://www.azonano.com/Advertising-pack.asp, 2007.
“Digitalis,” http://www.ch.ic.ac.uk/vchemlib/mim/bristol/digitalis/digitalis_text.htm.
[litigation document] Complaint and Exhibits Thereto;Élan Pharmaceutical International Limitedv.Abraxis Bioscience, Inc.,Jul. 19, 2006.
[litigation document] Docket Sheet inÉlan Pharmaceutical International Limitedv.Abraxis Bioscience, Inc.
[litigation document] Plaintiff Élan Pharma International Limited's Opening Claim Construction Brief;Élan Pharmaceutical International Limitedv.Abraxis B
de Garavilla Lawrence
Liversidge Elaine
Liversidge Gary G.
Azpuru Carlos A
Elan Pharma International Limited
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Reduction of intravenously administered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduction of intravenously administered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of intravenously administered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165670